Vétoquinol SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0004186856
EUR
77.00
-0.2 (-0.26%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 52.59

 
2

Healthy long term growth as Net Sales has grown by an annual rate of 5.45%

 
3

Flat results in Dec 24

4

With ROE of 10.68%, it has a Attractive valuation with a 1.65 Price to Book Value

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 844 Million ()

stock-summary
P/E

15.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

1.25%

stock-summary
Debt Equity

-0.31

stock-summary
Return on Equity

10.68%

stock-summary
Price to Book

1.49

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-5.17%
0%
-5.17%
6 Months
5.62%
0%
5.62%
1 Year
0%
0%
0.0%
2 Years
-14.54%
0%
-14.54%
3 Years
-8.98%
0%
-8.98%
4 Years
-41.58%
0%
-41.58%
5 Years
-7.0%
0%
-7.0%

Vétoquinol SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
5.45%
EBIT Growth (5y)
9.60%
EBIT to Interest (avg)
52.59
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.34
Sales to Capital Employed (avg)
1.02
Tax Ratio
25.25%
Dividend Payout Ratio
17.89%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
18.10%
ROE (avg)
10.04%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
1.65
EV to EBIT
10.46
EV to EBITDA
7.24
EV to Capital Employed
1.94
EV to Sales
1.44
PEG Ratio
0.54
Dividend Yield
1.13%
ROCE (Latest)
18.56%
ROE (Latest)
10.68%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Vétoquinol SA"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 1.87% vs -1.95% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 5.58% vs 15.83% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "539.20",
          "val2": "529.30",
          "chgp": "1.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "102.30",
          "val2": "97.30",
          "chgp": "5.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.20",
          "val2": "1.10",
          "chgp": "9.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.80",
          "val2": "-3.60",
          "chgp": "77.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "58.70",
          "val2": "55.60",
          "chgp": "5.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "130.50%",
          "val2": "124.20%",
          "chgp": "0.63%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
539.20
529.30
1.87%
Operating Profit (PBDIT) excl Other Income
102.30
97.30
5.14%
Interest
1.20
1.10
9.09%
Exceptional Items
-0.80
-3.60
77.78%
Consolidate Net Profit
58.70
55.60
5.58%
Operating Profit Margin (Excl OI)
130.50%
124.20%
0.63%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 1.87% vs -1.95% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 5.58% vs 15.83% in Dec 2023

stock-summaryCompany CV
About Vétoquinol SA stock-summary
stock-summary
Vétoquinol SA
Pharmaceuticals & Biotechnology
Vetoquinol SA is a France-based company that specializes in the research, development, manufacture, marketing and sale of veterinary drugs and products. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine, intended for dogs and cats, and Tolfine for livestock, and cardiovascular and nephrology treatment, such as Prilium, an oral daily administration formula for dogs, among others. The Company markets over 700 products, in such countries as France, Austria, Canada, Italy, Poland, Spain and the Netherlands, among others. It trades its products throughout Europe, North America, Africa, the Middle East and Pacific Asia. In April 2014, it acquired Bioniche's animal health business.
Company Coordinates stock-summary
Company Details
Sainte-Anne 34 rue du Chene, Bp 189, Lure Cedex LURE None : 70204
stock-summary
Tel: 33 3 84625555
stock-summary
Registrar Details